Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) filed a Form 8-K with the Securities and Exchange Commission on March 06, 2026, disclosing a material event.
Drugs Made In America Acquisition Corp.'s stock currently trades at $10.47 with a market capitalization of $347.2M. The Financial Services company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Drugs Made In America Acquisition Corp.'s stock.
All SEC filings for Drugs Made In America Acquisition Corp. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.